The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Edwards Lifesciences (NYSE: EW) shares stayed put after hours today on first-quarter results that beat Wall Street ...

Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights. Q1 ...

Edwards Lifesciences Corp (EW) reports an 8% increase in total sales, raises full-year guidance, and achieves significant ...

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

Edwards reaffirmed its 2025 adjusted per-share profit of $2.40 to $2.50, taking into account the $1.2 billion deal to buy heart device makers JenaValve and Endotronix, and tariff impact.

The company expects pressure on its operating margin as a result of the weakening dollar, the impact of announced tariffs and the expected close of the JenaValve acquisition. However, the company ...

The Heart Valve Devices Market is valued at USD 12.18 Billion in 2024 and is expected to reach USD 41.88 Billion by 2035 at a ...